184 related articles for article (PubMed ID: 20439606)
1. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
[TBL] [Abstract][Full Text] [Related]
3. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
[TBL] [Abstract][Full Text] [Related]
6. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F; Martinez R; Peters S; Sudre P; Telenti A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
[TBL] [Abstract][Full Text] [Related]
8. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
[TBL] [Abstract][Full Text] [Related]
9. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
10. Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
Lastere S; Dalban C; Collin G; Descamps D; Girard PM; Clavel F; Costagliola D; Brun-Vezinet F;
Antivir Ther; 2004 Apr; 9(2):221-7. PubMed ID: 15134184
[TBL] [Abstract][Full Text] [Related]
11. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
McKinnon JE; Delgado R; Pulido F; Shao W; Arribas JR; Mellors JW
Antivir Ther; 2011; 16(5):725-32. PubMed ID: 21817194
[TBL] [Abstract][Full Text] [Related]
12. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
13. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
Ho SK; Perez EE; Rose SL; Coman RM; Lowe AC; Hou W; Ma C; Lawrence RM; Dunn BM; Sleasman JW; Goodenow MM
AIDS; 2009 Aug; 23(13):1631-40. PubMed ID: 19625947
[TBL] [Abstract][Full Text] [Related]
14. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
[TBL] [Abstract][Full Text] [Related]
15. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.
Knops E; Brakier-Gingras L; Schülter E; Pfister H; Kaiser R; Verheyen J
Med Microbiol Immunol; 2012 May; 201(2):213-8. PubMed ID: 22200908
[TBL] [Abstract][Full Text] [Related]
16. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
Teto G; Nka AD; Fokam J; Bouba Y; Takou D; Fabeni L; Carioti L; Armenia D; Semengue ENJ; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Ndjolo A
Sci Rep; 2022 Jan; 12(1):1374. PubMed ID: 35082353
[TBL] [Abstract][Full Text] [Related]
17. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
Malet I; Roquebert B; Dalban C; Wirden M; Amellal B; Agher R; Simon A; Katlama C; Costagliola D; Calvez V; Marcelin AG
J Infect; 2007 Apr; 54(4):367-74. PubMed ID: 16875739
[TBL] [Abstract][Full Text] [Related]
18. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
Vray M; Meynard JL; Dalban C; Morand-Joubert L; Clavel F; Brun-Vézinet F; Peytavin G; Costagliola D; Girard PM;
Antivir Ther; 2003 Oct; 8(5):427-34. PubMed ID: 14640390
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Blanch-Lombarte O; Santos JR; Peña R; Jiménez-Moyano E; Clotet B; Paredes R; Prado JG
J Antimicrob Chemother; 2020 Sep; 75(9):2535-2546. PubMed ID: 32556165
[TBL] [Abstract][Full Text] [Related]
20.
Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]